Protein / target

Interleukin-4 receptor subunit alpha

IL4RP24394Homo sapiensSwiss-Prot
UniProt: P24394Ensembl: ENSG00000077238HGNC: HGNC:6015NCBI Gene: 3566
Clinically validated
Therapeutic maturity
1
Approved medicines
30
Clinical trials
Antibody-tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Interleukin-4 receptor activity

Primary system

Immune system

Strongest disease association

asthma

Genetic evidence · score 0.93

Therapeutic maturity

Clinically validated target

1 approved medicine against this target

Druggability

Antibody

Open Targets tractability · Approved Drug

Clinical development

1 approved · 1 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Receptor for both interleukin 4 and interleukin 13 (PubMed:17030238). Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2

Subcellular location

Cell membraneSecreted
Domains and Gene Ontology detail (17)

Domains & features

Fibronectin type-III

Gene Ontology

  • Cexternal side of plasma membrane
  • Cextracellular region
  • Cplasma membrane
  • Creceptor complex
  • Finterleukin-4 receptor activity
  • Pcell surface receptor signaling pathway via JAK-STAT
  • Pimmune response
  • Pinterleukin-13-mediated signaling pathway
  • Pinterleukin-4-mediated signaling pathway
  • Ppositive regulation of chemokine production
  • Ppositive regulation of cold-induced thermogenesis
  • Ppositive regulation of leukocyte differentiation

825 aa · 90 kDa · 3 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GO · ReactomeKinase signallingGO
View supporting evidence

Immune signalling

  • ·Receptor for both interleukin 4 and interleukin 13 (PubMed:17030238). Couples to the JAK…
  • ·interleukin-4 receptor activity
  • ·immune response
  • ·interleukin-13-mediated signaling pathway

Kinase signalling

  • ·positive regulation of tyrosine phosphorylation of STAT protein
View underlying pathways (2)
Interleukin-4 and Interleukin-13 signaling
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

IL13RA2STAT6JAK1IL2RGIL4IL13RA1IL13JAK3JAK2SOCS5IL4R

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

dupilumab
Narrow target profileApprovedAntagonist

Interleukin-4 receptor subunit alpha antagonist

Appears in clinical studies involving Nasal polyposis, atopic eczema, Eczematoid dermatitis, prurigo

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

asthma0.93

Genetic · overall 0.74

childhood onset asthma0.84

Genetic · overall 0.51

Wheezing0.80

Genetic · overall 0.49

respiratory system disorder0.79

Genetic · overall 0.51

lower respiratory tract disorder0.77

Genetic · overall 0.47

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

atopic eczema0.98

Clinical · overall 0.61

Nasal polyposis0.90

Clinical · overall 0.55

sinusitis0.77

Clinical · overall 0.47

Eczematoid dermatitis0.66

Clinical · overall 0.49

chronic rhinosinusitis0.15

Clinical · overall 0.49

Show all associations
asthma0.74
atopic eczema0.61
Nasal polyposis0.55
childhood onset asthma0.51
respiratory system disorder0.51
Eczematoid dermatitis0.49
Wheezing0.49
chronic rhinosinusitis0.49
lower respiratory tract disorder0.47
sinusitis0.47

Open Targets ranks 754 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 2 total

CINTREDEKIN BESUDOTOXPhase 3

brain cancer · anaplastic astrocytoma · glioblastoma

DUPILUMABApproval

Nasal polyposis · atopic eczema · Eczematoid dermatitis

Tractability

AB · Approved DrugAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · Database UbiquitinationOC · Advanced Clinical

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic WheezePHASE3

RECRUITING · via dupilumab · NCT06191315

A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic EsophagitisPHASE3

RECRUITING · via dupilumab · NCT07112378

Effects of IL-4R-alpha Inhibition (Dupixent) Inhibition On The Respiratory Microbiome And Immunologic Correlates In Patients With Severe AsthmaPHASE4

COMPLETED · via dupilumab · NCT05036733

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab StudyPHASE4

TERMINATED · via dupilumab · NCT03389893

A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic DermatitisPHASE1

ACTIVE_NOT_RECRUITING · via dupilumab · NCT07027527

A Randomized, Double-blind, Placebo-controlled, Proof of Concept, Multicenter, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Cholinergic Urticaria Despite H1-antihistamine TreatmentPHASE2

COMPLETED · via dupilumab · NCT03749148

Show remaining trials (24)
A Randomized, 52-Week Treatment Double-Blind, Placebo-Controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid SprayPHASE3

WITHDRAWN · via dupilumab · NCT06461949

IL-4 & Insulin Resistance in Patients With Atopic DermatitisEARLY_PHASE1

COMPLETED · via dupilumab · NCT05372003

A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic DermatitisPHASE2

TERMINATED · via dupilumab · NCT04791319

Dupilumab in the Treatment of Pediatric Alopecia AreataPHASE2

RECRUITING · via dupilumab · NCT05866562

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (ADRN-12)PHASE4

COMPLETED · via dupilumab · NCT05436535

A Randomized, Double-blind, Single-dose, Parallel Comparison Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Chinese Adult Male SubjectsPHASE1

NOT_YET_RECRUITING · via dupilumab · NCT07334496

A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants (≥6 to <15 Years of Age) With Moderate-to-severe Atopic DermatitisPHASE4

ACTIVE_NOT_RECRUITING · via dupilumab · NCT05983068

A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE)PHASE4

ACTIVE_NOT_RECRUITING · via dupilumab · NCT06101095

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity ReactionPHASE4

COMPLETED · via dupilumab · NCT06012448

A Phase 1 Dose-Escalation Study in Adults With Severe IgE-Mediated Food Allergy, to Assess the Safety, Tolerability, and Pharmacodynamic Effects of Short-Term Linvoseltamab Treatment, a BCMAxCD3 Bispecific Antibody to Induce T-Cell Killing of IgE Producing Plasma Cells, on Top of Chronic Dupilumab Treatment, to Prevent the Formation of New IgE Producing Plasma CellsPHASE1

ACTIVE_NOT_RECRUITING · via dupilumab · NCT06369467

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic DermatitisPHASE3

COMPLETED · via dupilumab · NCT03054428

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisPHASE2

COMPLETED · via dupilumab · NCT01979016

A Phase 1/2 Study of Combined Treatment With Dupilumab (Anti-IL-4Ra) and Cemiplimab (Anti-PD-1) in Patients With Early-stage, Resectable NSCLCPHASE1/PHASE2

RECRUITING · via dupilumab · NCT06088771

An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic DermatitisPHASE4

COMPLETED · via dupilumab · NCT05590585

A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic DermatitisPHASE2

COMPLETED · via dupilumab · NCT01548404

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe AsthmaPHASE4

ACTIVE_NOT_RECRUITING · via dupilumab · NCT05097287

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled AsthmaPHASE2

COMPLETED · via dupilumab · NCT01854047

A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut AllergyPHASE2

COMPLETED · via dupilumab · NCT03793608

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous PemphigoidPHASE2/PHASE3

COMPLETED · via dupilumab · NCT04206553

A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsPHASE2

RECRUITING · via dupilumab · NCT06477653

An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic DermatitisPHASE1

COMPLETED · via dupilumab · NCT03050151

A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge ModelPHASE2

COMPLETED · via dupilumab · NCT03558997

A Randomized, Placebo-controlled, Parallel Panel Study to Assess the Effects of REGN3500, Dupilumab, and Combination of REGN3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic AsthmaPHASE1

COMPLETED · via dupilumab · NCT03112577

Safety and Efficacy of the Treatment of Hospitalized Patients With COVID 19 Infection With an Inhibitor of IL-4 and IL-13 Signaling: A Phase IIa TrialPHASE2

COMPLETED · via dupilumab · NCT04920916

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

asthmaWell supported
0.98
agreement 0.89–1.00
Genetic48%Clinical38%Animal model8%Literature5%

Open Targets aggregate 0.74 · 4 independent evidence families

childhood onset asthmaWell supported
0.84
agreement 0.70–0.98
Genetic98%Literature2%

Open Targets aggregate 0.51 · 2 independent evidence families

respiratory system disorderWell supported
0.82
agreement 0.71–0.93
Genetic86%Clinical13%Literature1%

Open Targets aggregate 0.51 · 3 independent evidence families

WheezingWell supported
0.80
agreement 0.68–0.92
Genetic100%

Open Targets aggregate 0.49 · 1 independent evidence family

Eczematoid dermatitisWell supported
0.79
agreement 0.69–0.90
Genetic53%Clinical45%Literature2%

Open Targets aggregate 0.49 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

48

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Industry development2026-07-15
    Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent

    Fierce Biotech · news · via dupilumab

  2. Label change2026-07-15

    Label change: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  3. Indication expanded2026-04-22

    Indication expansion: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  4. Label change2026-04-16

    Label change: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  5. Indication expanded2026-02-23

    Indication expansion: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  6. Indication expanded2025-06-18

    Indication expansion: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  7. Indication expanded2025-04-17

    Indication expansion: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  8. Label change2025-04-16

    Label change: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  9. Indication expanded2024-09-27

    Indication expansion: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  10. Indication expanded2024-09-12

    Indication expansion: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  11. Label change2024-04-12

    Label change: DUPILUMAB (BLA761055)

    fda · regulatory · fda · via dupilumab

  12. New publication2024-04-02
    Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells.

    Nature communications · 2024 · 43 citations · Europe PMC · via dupilumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.